Possible erythromelalgia-like syndrome associated with nifedipine in a patient with Raynaud's phenomenon

OBJECTIVE: To describe a patient who was diagnosed with Raynaud's phenomenon, was prescribed immediate-release nifedipine, and developed a possible erythromelalgia-like syndrome. CASE SUMMARY: A 24-year-old white woman with a history of esophageal spasms and Raynaud's phenomenon was prescribed nifedipine 10 mg po qid. Approximately 1 hour after the patient had taken the fourth dose of nifedipine, she experienced acute erythema and a burning sensation in her feet and lower limbs, light-headedness, and palpitations. Because of a reportedly abnormally low blood pressure, the patient took diphenhydramine 50 mg po and proceeded to the clinic. On arrival, abnormal vital signs were BP 140/48 mm Hg and HR 130 beats/min. Without any other medical intervention, approximately 30 minutes later her blood pressure and heart rate had returned to baseline at 122/60 mm Hg and 96 beats/min, respectively. The nifedipine was permanently discontinued and the patient's symptoms completely resolved over 24 hours. DISCUSSION: The characteristic symptoms of erythromelalgia include burning pain, increased skin temperature, and erythema of the extremities, usually to the feet, lower legs, and, less often, the hands. Erythromelalgia-like syndromes secondary to the administration of many medications have been reported. Several nifedipine-related reports describe an erythromelalgia-like syndrome similar to our reported case. CONCLUSIONS: Because the patient was not taking any other medications and the symptoms started with the administration of nifedipine and were relieved after its discontinuation, nifedipine was thought to be the cause of the erythromelalgia-like syndrome.

This article has been cited by other articles:

				M. D. P. Davis, F. Wilkins, and T. W. Rooke Between episodes of erythromelalgia: a spectrum of colors. Arch Dermatol, August 1, 2006; 142(8): 1085 - 1086. [Full Text] [PDF]

				J. Rey, E. Cretel, R. Jean, M.-J. Pastor, and J.-M. Durand Serotonin reuptake inhibitors, Raynaud's phenomenon and erythromelalgia Rheumatology, April 1, 2003; 42(4): 601 - 602. [Full Text] [PDF]

				D. Hayoz, G. Bizzini, B. Noel, M. Depairon, M. Burnier, C. Fauveau, A. Rouillon, R. Brouard, and H. R. Brunner Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon Rheumatology, October 1, 2000; 39(10): 1132 - 1138. [Abstract] [Full Text] [PDF]